Elevating your insights into human cell biology requires a rethinking of each cell model. Presented in 2021, this more predictive and biologically relevant airway epithelial-endothelial model might allow scientists to better understand how our pulmonary system responses to diseases like COVID-19, COPD, asthma, cystic fibrosis and more.
For the first time, scientists are co-culturing Calu-3 cells and Primary Human Lung Microvascular Endothelial Cells (from Cell Systems Cat# ACBRI 468) on flexible porous PTMC membranes to build a new airway epithelial-endothelial model that better reflects the lungs’ complexity.
Many existing models involve culturing lung epithelial cells on stiff membranes, which is not the most ideal system. Not only does this not mimic the flexibility of breathing lungs, it also neglects the interaction between the epithelium and endothelium.
The new model from this study sees an improved barrier function thanks to the addition of Primary Human LMVECs. Furthermore, both the Calu-3 cells and LMVECs grown on flexible PTMC membranes have high cell viability and express ZO-1 and CD31 respectively. There is also no detection of epithelial- and endothelial-to-mesenchymal transition. Overall, this promising model can be the foundation for more insightful pulmonary research.
The incorporation of primary human cells into such models is ideal because of their advanced biological relevance.
To further preserve these cells’ original properties, Cell Systems provides gold-standard human primary cells that are free of antibody labels. Plus, our unadulterated cells are easy to culture, are widely cited and have high viability!
To see how primary human cells can enhance consistency and reproducibility in your research of the pulmonary system, check out Cell Systems Primary Human Lung Microvascular Endothelial Cells (ACBRI 468) and our brand new product Primary Human Lung Fibroblast (ACBRI 469).